Comparative pharmacoeconomic analysis of metastatic colorectal cancer treatment
- Authors: Petukhova Y.Y.1,2, Eliseeva E.V.1, Apanasevich V.I.1, Petukhova A.G.1, Ovodova A.V.1
-
Affiliations:
- Pacific State Medical University
- Primorskiy Regional Oncological Dispensary
- Issue: Vol 23, No 4 (2021)
- Pages: 213-220
- Section: Public Health
- Submitted: 25.02.2021
- Accepted: 30.10.2021
- Published: 15.12.2021
- URL: https://journals.eco-vector.com/1682-7392/article/view/61805
- DOI: https://doi.org/10.17816/brmma61805
- ID: 61805
Cite item
Abstract
Every year, the pharmacological market offers new medicines to increase the survival rate and improve the quality of life of patients with cancer. However, while significantly exceeding the cost of existing methods of pharmacotherapy, new technologies often lead to only a small increased efficiency. Budget resources of health care dictate the need for a rational choice of pharmacotherapeutic options for malignant neoplasms that meet the principles of ensuring maximum results and accessibility for the entire population. An important role in solving this problem is played by such a direction of pharmacoeconomic analysis as the “cost-effectiveness” method. Colorectal cancer is one of the three oncological diseases that cause the greatest socio-economic burden for the state, which is associated with the highest costs of the Russian Federation health care system. Concurrently, in the last decade, a much more favorable prognosis has been identified for patients with metastatic colorectal cancer due to the development of effective approaches to antitumor pharmacotherapy. Conducting a pharmacoeconomic review that takes into account both clinical and economic indicators when using classic chemotherapy regimens and new targeted drugs will determine the effectiveness of finances that are spent to combat this malignancy. Additionally, the need to further individualize the therapy of patients suffering from metastatic colorectal cancer and lower prices for modern antitumor drugs is undeniable.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Yulia Yu. Petukhova
Pacific State Medical University; Primorskiy Regional Oncological Dispensary
Author for correspondence.
Email: juliapetukhovavl@mail.ru
ORCID iD: 0000-0002-0724-9736
postgraduate student
Russian Federation, Vladivostok; VladivostokEkaterina V. Eliseeva
Pacific State Medical University
Email: yeliseeff23@gmail.com
ORCID iD: 0000-0001-6126-1253
SPIN-code: 1332-1667
doctor of medical sciences, professor
Russian Federation, VladivostokVladimir I. Apanasevich
Pacific State Medical University
Email: oncolog222@gmail.com
ORCID iD: 0000-0003-0808-5283
SPIN-code: 3708-6497
doctor of medical sciences
Russian Federation, VladivostokAntonina G. Petukhova
Pacific State Medical University
Email: petukhova_antoninagl@mail.ru
ORCID iD: 0000-0002-0387-098X
SPIN-code: 5487-9104
student
Russian Federation, VladivostokAnna V. Ovodova
Pacific State Medical University
Email: ovodovanna@mail.ru
ORCID iD: 0000-0002-0943-832X
SPIN-code: 5487-9010
resident
Russian Federation, VladivostokReferences
- Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021;18(10):663–672. doi: 10.1038/s41571-021-00514-z
- Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. Kaprin AD, Stalinskiy VV, Shahzadova AO. editors. Moscow: MNIOI im PA Gercena. filial FGBU NMIC radiologii Minzdrava Rossii; 2020. 239 p. (In Russ.).
- Andreev DA, Polyakova KI, Zavyalov AA, et al. The main directions of the analysis of economic costs in the provision of oncological care to the population. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(4):310−317. (In Russ.). doi: 10.17749/2070-4909.2019.12.4.310-317
- Feldblum IV, Alyeva MKh, Radionova MV. Complex influence of medico-social and environmental risk factors on the probability of colorectal cancer development. Pacific Medical Journal. 2018;(3):24−28. (In Russ.). doi: 10.17238/pmj1609-1175.2018.3.24-28
- Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis. JAMA Oncol. 2017;3(4):524–548. doi: 10.1001/jamaoncol.2016.5688
- Blinov DV, Akarachkova ES, Orlova AS, et al. New framework for the development of clinical guide lines in Russia. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(2):125–144. (In Russ.). doi: 10.17749/2070-4909.2019.12.2.125-144
- Omelyanovsky VV, Avksentyeva MV, SuraMV, et al. Approaches to the formation of a unified methodology for calculating incremental indicators “costs/efficiency” on the example of antitumor drugs in the framework of revising the lists of medicines for medical use. Medical technologies. Evaluation and Selection. 2018;(1):10–20. (In Russ.). doi: 10.17116/medtech12018131110
- Serpik VG, Yagudina RI, KulikovA Yu. Pharmacoeconomics of innovations or innovations in pharmacoeconomics: a “relative value” analysis instead of a “cost-effectiveness” analysis? Farmakoekonomika: teoriya i praktika. 2019;2:5–8. (In Russ.). doi: 10.30809/phe.2.2019.1
- Zaplutanov VA, Litovkin AV, Belov VG, et al. Quality of life in elderly and senile cancer patients. PA. Herzen Journal of Oncology. 2016;2:25–28. (In Russ.).
- Zadlo J. Cost-effectiveness of new and emerging treatment options for metastatic colorectal cancer. Am J Manag Care. 2018;24(7):118–124.
- Sherman SK, Lange JJ, Dahdaleh FS, et al. Cost-effectiveness of maintenance capecitabine and bevacizumab in metastatic colorectal cancer. JAMA Oncology. 2019;5(2):236–242. doi: 10.1001/jamaoncol.2018.5070
- Tryakin AA, Balunov PA. Pharmacoeconomical assessment of the use of targeted therapy and chemotherapy. Medical Council. 2018;19:50–55. (In Russ.) doi: 10.21518/2079-701X-2018-19-50-55
- Fedyanin MYu, Tryakin AA, Rogov VA, et al. Pharmacoeconomical features of the choice of systemic therapy in patients with metastatic colon cancer. Colorectaloncology. 2017;7(2):36–42. (In Russ.). doi: 10.17650/2220-3478-2017-7-2-36-42
- Avksentiev NA, Derkach EV, Pyadushkina EA, Ter-Ovanesov MD. The cost of treatment of metastatic colorectal cancer in the second and subsequent lines of therapy using targeted drugs. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2016;9(2):38–44. (In Russ.). doi: 10.17749/2070-4909.2016.9.2.038-044
- Byrne M, Saif MW. Selecting treatment options in refractory metastatic colorectal cancer. OncoTargets and Therapy. 2019;12:2271–2278. doi: 10.2147/OTT.S194605
- Gorchakov SV, Jusudov IV, Vasiliev SV et al. Long-term results and prognostic factors-their influence on the choice of treatment tactics for patients with colorectal cancer with liver metastases. Povolzhsky Oncological Bulletin. 2016;(1):29–37. (In Russ.). DOI: 616.34/.35-006.6-06:616.36-033.2
- Fedenko AA, Tryakin AA, Zhukova LG, et al. Nacional’noe rukovodstvo po lekarstvennomu lecheniju zlokachestvennyh opuholej. Kaprin AD, editor. Moscow; 2020. 408 p. (In Russ.).
- Huxley N, Crathorne L, Varley-Campbell J, et al. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment. 2017;21(38). doi: 10.3310/hta21380
- Ungari AQ, Pereira LRL, Nunes AA, Peria FM. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. BMC Cancer. 2017;17:691. doi: 10.1186/s12885-017-3679-5
- Shida T, Endo Y, Shiraishi T, et al. Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis. Yakugaku Zassi. 2018;138(1):83–90. doi: 10.1248/Yakushi.17-00159
- Goldstein DA, Chen QS, Iyer T, et al. Bevacizumab for metastatic colorectal cancer: a global cost-effectiveness analysis. Тhe Oncologist. 2017;22(6):694–699. doi: 10.1634/theoncologist.2016-0455
- Calcagno F, Lenoble S, Lakkis Z, et al. Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice. Libertas Academica. 2016;10:59–66. doi: 10.4137/CMO.S38335
- Overman MJ, Dermott RM, André T. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability – high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study. The Lanset Oncologi. 2017;18(9):510. doi: 10.1016/S1470-2045(17) 30638-1
- Tintelnot J, Stein A. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. World J Gastroenterol. 2019;25(29):3920–3928. doi: 10.3748/wjg.v25.i29.3920
Supplementary files
![](/img/style/loading.gif)